Cyberounds Logo
November 17, 2019 | LOGIN | REGISTER | HELP | 


email a friend print Bookmark and Share
The Treatment of Insomnia
CME credit is no longer available for this conference.
Andrew D. Krystal, M.D., M.S.

Dr. Krystal is the Director, Insomnia and Sleep Research Program, and Associate Professor with Tenure in Psychiatry and Behavioral Sciences, Duke University School of Medicine.

Within the past 12 months, Dr. Krystal reports research grant support, consulting relationship or advisory board member for Sanofi-Aventis, GlaxoSmithKline, King Pharmaceuticals, Inc., Merck & Co., Inc., Cephalon, Inc., Eli Lilly, Neurocrine Biosciences, Inc., Sepracor Inc., Pfizer Inc., Johnson & Johnson, Organon, Takeda Pharmaceuticals North America, Inc., Respironics, Neuronetics, Transoral, Neurogen, Somaxon, Research Triangle Institute and Novartis.


Release Date: 07/08/2007
Termination Date: 07/08/2010

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe new developments in research that have implications for changing the clinical management of insomnia
  • Discuss strategies for optimal clinical management of insomnia
  • Discuss the therapies that are available for the clinical management of insomnia and how to decide which to use in a given patient.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity